AVTX: Avalo Therapeutics, Inc. Stock

by  •  • Comments Off on AVTX: Avalo Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 76.70
Enterprise Value ($M) -3.50
Book Value ($M) 22.73
Book Value / Share 2.17
Price / Book 3.37
NCAV ($M) 10.43
NCAV / Share 1.00
Price / NCAV 7.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.33
Return on Assets (ROA) -0.38
Return on Equity (ROE) -1.09

Liquidity (mrq)
Quick Ratio 1.42
Current Ratio 1.42

Balance Sheet (mrq) ($M)
Current Assets 86.15
Assets 98.45
Liabilities 75.72
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Biotechnology Value Fund L P 9.99 7.37
12-31 13G Affinity Asset Advisors, LLC 5.30
11-14 13G/A Allostery Investments LP 0.50 -28.64
11-14 13G Orbimed Advisors Llc 9.90
11-07 13G/A Crutcher Patrick J 5.60 395.68
10-07 13G Ikarian Capital, LLC 10.02
08-23 13G Ra Capital Management, L.p. 9.99
04-23 13G Emerald Bioventures, LLC 5.60
04-05 13G Deep Track Capital, LP 9.99
2024-02-14 13G/A Venrock Healthcare Capital Partners III, L.P. 0.00 -100.00
2024-02-14 13G/A Nantahala Capital Management, LLC 4.90 -93.57
2024-02-14 13G/A Great Point Partners Llc 0.26
2024-02-14 13G/A Point72 Asset Management, L.P. 0.30 -99.96

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUAN
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-07-11 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 25,203 123,430 20.42
2025-03-06 4,220 21,232 19.88
2025-03-05 4,572 27,968 16.35
2025-03-04 5,844 24,092 24.26

(click for more detail)

Similar Companies
ATOS – Atossa Therapeutics, Inc. ATXI – Avenue Therapeutics, Inc.
ATYR – aTyr Pharma, Inc. AWH – Aspira Women's Health Inc.
AYTU – Aytu BioPharma, Inc.


Financial data and stock pages provided by
Fintel.io